BioVersys AG (XSWX:BIOV) Revenue: CHF0.80 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BIOV BioVersys AG XSWX:BIOV
4 GF Score
Price CHF27.70
View Full Analysis

What is BioVersys AG Revenue?

BioVersys AG XSWX:BIOV +0.73% 4 Revenue is CHF0.80 Mil as of Dec. 2025. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100.

BioVersys AG's revenue for the six months ended in Dec. 2025 was CHF0.80 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.80 Mil. BioVersys AG's Revenue per Share for the six months ended in Dec. 2025 was CHF0.14. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.14.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

BioVersys AG  (XSWX:BIOV) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

BioVersys AG Revenue Related Terms

BioVersys AG Revenue Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Revenue Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Revenue
0.00 0.80

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Revenue 0.00 0.00 0.00 0.80

XSWX:BIOV vs VRTX, REGN, ALNY: Revenue Comparison

For the Biotechnology subindustry, BioVersys AG's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVersys AG Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVersys AG's Revenue distribution charts can be found below:

* The bar in red indicates where BioVersys AG's Revenue falls into.


XSWX:BIOV
4GF Score
BioVersys AG XSWX:BIOV
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of CHF0.80 Mil mean?
BioVersys AG (XSWX:BIOV) has a Revenue of CHF0.80 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on BioVersys AG and its competitors.
Is BioVersys AG's Revenue too high?
BioVersys AG's current Revenue is CHF0.80 Mil. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Revenue compare to VRTX and REGN?
BioVersys AG's Revenue of CHF0.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on BioVersys AG and its competitors. BioVersys AG's current Revenue is CHF0.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current Revenue of CHF0.80 Mil. The current Revenue is CHF0.80 Mil. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current Revenue is CHF0.80 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score

Get the complete analysis for XSWX:BIOV

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF27.70
Price